Concepedia

Göril Karlsson

GK

9

Publications

554

Citations

9

H-Index

1988

Active since

Affiliations

Novartis (Switzerland)(Current)

Université de Lille

Queen Mary University of London

University of Basel

University of Pennsylvania

Göril Karlsson is an author at Novartis (Switzerland) specializing in neuropharmacology, medicine, and neuroscience.

Top concepts

Publications per year

1988–2022

9

Publications

9

CGP 35348: a centrally active blocker of GABAB receptors

Hans-Rudolf Olpe, Göril Karlsson, Mario F. Pozza et al. · European Journal of Pharmacology · 1990 · 309 citations

, , +5

Siponimod and Cognition in Secondary Progressive Multiple Sclerosis

Ralph H. B. Benedict, Davorka Tomic, Bruce Cree et al. · Neurology · 2021 · 77 citations

Phaclofen: a GABAB blocker reduces long-duration inhibition in the neocortex

Göril Karlsson, Mario F. Pozza, Hans-Rudolf Olpe · European Journal of Pharmacology · 1988 · 42 citations

, , +7

Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial

Douglas L. Arnold, Daniela Piani-Meier, Amit Bar‐Or et al. · Multiple Sclerosis Journal · 2022 · 32 citations · Full text

Inhibitory processes in normal and epileptic-like rat hippocampal slices: the role of GABAB receptors

Göril Karlsson, Hans-Rudolf Olpe · European Journal of Pharmacology · 1989 · 27 citations

, , +13

Rows per page

1–5 of 9